Patents by Inventor Tomohisa Watanabe
Tomohisa Watanabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160340398Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.Type: ApplicationFiled: August 4, 2016Publication date: November 24, 2016Inventors: TAKUYA TSUNODA, RYUJI OHSAWA, SACHIKO YOSHIMURA, TOMOHISA WATANABE, YUSUKE NAKAMURA, YOICHI FURUKAWA
-
Publication number: 20160343470Abstract: Disclosed is a flame retardant resin composition comprising: a polyolefin resin; a silicone-based compound blended at a ratio of 3 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; calcium carbonate blended at a ratio of 10 parts by mass or more and less than 100 parts by mass relative to 100 parts by mass of the polyolefin resin; and aluminum hydroxide blended at a ratio of 5 parts by mass or more and 60 parts by mass or less relative to 100 parts by mass of the polyolefin resin.Type: ApplicationFiled: December 3, 2014Publication date: November 24, 2016Applicant: FUJIKURA, LTD.Inventors: Haruka KOHRI, Masayuki IWATA, Tomohisa WATANABE
-
Publication number: 20160310586Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.Type: ApplicationFiled: July 6, 2016Publication date: October 27, 2016Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Patent number: 9458447Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides.Type: GrantFiled: August 9, 2012Date of Patent: October 4, 2016Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura
-
Patent number: 9446106Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.Type: GrantFiled: April 17, 2015Date of Patent: September 20, 2016Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
-
Patent number: 9427461Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.Type: GrantFiled: October 25, 2012Date of Patent: August 30, 2016Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Patent number: 9403890Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids.Type: GrantFiled: March 11, 2014Date of Patent: August 2, 2016Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20160008445Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e.Type: ApplicationFiled: March 11, 2014Publication date: January 14, 2016Inventors: Takuya TSUNODA, Ryuji OSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE
-
Publication number: 20150374810Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.Type: ApplicationFiled: July 27, 2015Publication date: December 31, 2015Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Patent number: 9187556Abstract: As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.Type: GrantFiled: June 7, 2012Date of Patent: November 17, 2015Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama, Yusuke Nakamura
-
Publication number: 20150322112Abstract: Peptide vaccines against cancer are described herein. Isolated epitope peptides derived from the SEMA5B gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The peptides encompass both SEMA5B-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for use in cancer immunotherapy.Type: ApplicationFiled: December 2, 2013Publication date: November 12, 2015Inventors: Takuya TSUNODA, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20150318076Abstract: Provided is a flame retardant resin composition which contains a base resin, calcium carbonate particles which are blended at a proportion of 10 to 150 parts by mass relative to 100 parts by mass of the base resin, a silicone-based compound which is blended at a proportion of 0.5 to 10 parts by mass relative to 100 parts by mass of the base resin, and a fatty acid-containing compound which is blended at a proportion of 1 to 20 parts by mass relative to 100 parts by mass of the base resin. In this flame retardant resin composition, the calcium carbonate particles have an average particle diameter of less than 0.7 ?m.Type: ApplicationFiled: December 20, 2013Publication date: November 5, 2015Applicant: FUJIKURA LTD.Inventors: Masayuki IWATA, Tomohisa WATANABE, Kazuya HOSHINO
-
Publication number: 20150315239Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.Type: ApplicationFiled: July 21, 2015Publication date: November 5, 2015Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20150290307Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.Type: ApplicationFiled: April 17, 2015Publication date: October 15, 2015Inventors: Takuya TSUNODA, Ryuji OHSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE, Yusuke NAKAMURA, Yoichi FURUKAWA
-
Patent number: 9125849Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.Type: GrantFiled: November 25, 2011Date of Patent: September 8, 2015Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Patent number: 9115207Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.Type: GrantFiled: May 23, 2013Date of Patent: August 25, 2015Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20150174223Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: ApplicationFiled: September 9, 2013Publication date: June 25, 2015Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 9056890Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.Type: GrantFiled: October 20, 2011Date of Patent: June 16, 2015Assignee: OncoTherapy Science Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 9045557Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.Type: GrantFiled: March 15, 2010Date of Patent: June 2, 2015Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
-
Patent number: 8951975Abstract: Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.Type: GrantFiled: March 30, 2011Date of Patent: February 10, 2015Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe